Department of General and Visceral Surgery, Ulm University Hospital , Ulm , Germany.
Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany.
Cochrane Database Syst Rev. 2022 Jan 11;1(1):CD011862. doi: 10.1002/14651858.CD011862.pub3.
Pancreatic cancer remains one of the five leading causes of cancer deaths in industrialised nations. For adenocarcinomas in the head of the gland and premalignant lesions, partial pancreaticoduodenectomy represents the standard treatment for resectable tumours. The gastro- or duodenojejunostomy after partial pancreaticoduodenectomy can be reestablished via either an antecolic or retrocolic route. The debate about the more favourable technique for bowel reconstruction is ongoing.
To compare the effectiveness and safety of antecolic and retrocolic gastro- or duodenojejunostomy after partial pancreaticoduodenectomy.
In this updated version, we conducted a systematic literature search up to 6 July 2021 to identify all randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library 2021, Issue 6, MEDLINE (1946 to 6 July 2021), and Embase (1974 to 6 July 2021). We applied no language restrictions. We handsearched reference lists of identified trials to identify further relevant trials, and searched the trial registries clinicaltrials.govand World Health Organization International Clinical Trials Registry Platform for ongoing trials.
We considered all RCTs comparing antecolic with retrocolic reconstruction of bowel continuity after partial pancreaticoduodenectomy for any given indication to be eligible.
Two review authors independently screened the identified references and extracted data from the included trials. The same two review authors independently assessed risk of bias of included trials, according to standard Cochrane methodology. We used a random-effects model to pool the results of the individual trials in a meta-analysis. We used odds ratios (OR) to compare binary outcomes and mean differences (MD) for continuous outcomes.
Of a total of 287 citations identified by the systematic literature search, we included eight randomised controlled trials (reported in 11 publications), with a total of 818 participants. There was high risk of bias in all of the trials in regard to blinding of participants and/or outcome assessors and unclear risk for selective reporting in six of the trials. There was little or no difference in the frequency of delayed gastric emptying (OR 0.67; 95% confidence interval (CI) 0.41 to 1.09; eight trials, 818 participants, low-certainty evidence) with relevant heterogeneity between trials (I=40%). There was little or no difference in postoperative mortality (risk difference (RD) -0.00; 95% CI -0.02 to 0.01; eight trials, 818 participants, high-certainty evidence); postoperative pancreatic fistula (OR 1.01; 95% CI 0.73 to 1.40; eight trials, 818 participants, low-certainty evidence); postoperative haemorrhage (OR 0.87; 95% CI 0.47 to 1.59; six trials, 742 participants, low-certainty evidence); intra-abdominal abscess (OR 1.11; 95% CI 0.71 to 1.74; seven trials, 788 participants, low-certainty evidence); bile leakage (OR 0.82; 95% CI 0.35 to 1.91; seven trials, 606 participants, low-certainty evidence); reoperation rate (OR 0.68; 95% CI 0.34 to 1.36; five trials, 682 participants, low-certainty evidence); and length of hospital stay (MD -0.21; 95% CI -1.41 to 0.99; eight trials, 818 participants, low-certainty evidence). Only one trial reported quality of life, on a subgroup of 73 participants, also without a relevant difference between the two groups at any time point. The overall certainty of the evidence was low to moderate, due to some degree of heterogeneity, inconsistency and risk of bias in the included trials.
AUTHORS' CONCLUSIONS: There was low- to moderate-certainty evidence suggesting that antecolic reconstruction after partial pancreaticoduodenectomy results in little to no difference in morbidity, mortality, length of hospital stay, or quality of life. Due to heterogeneity in definitions of the endpoints between trials, and differences in postoperative management, future research should be based on clearly defined endpoints and standardised perioperative management, to potentially elucidate differences between these two procedures. Novel strategies should be evaluated for prophylaxis and treatment of common complications, such as delayed gastric emptying.
胰腺癌仍然是工业化国家导致癌症死亡的五个主要原因之一。对于腺泡细胞癌在胰腺头部和癌前病变,部分胰十二指肠切除术是可切除肿瘤的标准治疗方法。部分胰十二指肠切除术后的胃或十二指肠空肠吻合术可以通过结肠前或结肠后途径重建。关于肠重建更有利的技术的争论仍在继续。
比较胰十二指肠切除术后结肠前和结肠后胃或十二指肠空肠吻合术的有效性和安全性。
在本次更新版本中,我们系统地检索了 Cochrane 中央对照试验注册库(CENTRAL)、Cochrane 图书馆 2021 年第 6 期、MEDLINE(1946 年至 2021 年 7 月 6 日)和 Embase(1974 年至 2021 年 7 月 6 日),以确定所有随机对照试验(RCT),截至 2021 年 7 月 6 日。我们没有语言限制。我们手工检索了确定的试验的参考文献,以确定其他相关试验,并在临床试验注册处 clinicaltrials.gov 和世界卫生组织国际临床试验注册平台上搜索正在进行的试验。
我们认为任何给定适应证下,将结肠前与结肠后重建肠连续性的胰十二指肠切除术进行比较的 RCT 均符合纳入标准。
两位综述作者独立筛选了确定的参考文献,并从纳入的试验中提取数据。同样的两位综述作者根据标准的 Cochrane 方法,独立评估了纳入试验的偏倚风险。我们使用随机效应模型对个体试验进行荟萃分析,将结果合并在一起。我们使用比值比(OR)比较二分类结局,使用均数差(MD)比较连续性结局。
通过系统文献检索共识别出 287 条引文,我们纳入了 8 项随机对照试验(发表在 11 篇出版物中),共有 818 名参与者。所有试验在参与者和/或结局评估者的盲法方面存在高偏倚风险,在 6 项试验中存在选择性报告的不确定风险。术后胃排空延迟的频率差异不大(OR 0.67;95%置信区间(CI)0.41 至 1.09;8 项试验,818 名参与者,低质量证据),且各试验间存在显著异质性(I=40%)。术后死亡率差异也不大(风险差(RD)-0.00;95%CI-0.02 至 0.01;8 项试验,818 名参与者,高质量证据);术后胰瘘(OR 1.01;95%CI 0.73 至 1.40;8 项试验,818 名参与者,低质量证据);术后出血(OR 0.87;95%CI 0.47 至 1.59;6 项试验,742 名参与者,低质量证据);腹腔脓肿(OR 1.11;95%CI 0.71 至 1.74;7 项试验,788 名参与者,低质量证据);胆漏(OR 0.82;95%CI 0.35 至 1.91;7 项试验,606 名参与者,低质量证据);再手术率(OR 0.68;95%CI 0.34 至 1.36;5 项试验,682 名参与者,低质量证据);以及住院时间(MD-0.21;95%CI-1.41 至 0.99;8 项试验,818 名参与者,低质量证据)。只有一项试验报告了 73 名参与者亚组的生活质量,且任何时间点两组间也没有相关差异。由于纳入试验存在一定程度的异质性、不一致性和偏倚风险,证据的总体确定性为低至中度。
低至中度质量证据表明,胰十二指肠切除术后结肠前重建与发病率、死亡率、住院时间或生活质量的差异不大。由于试验之间终点的定义存在差异,以及术后管理的差异,未来的研究应该基于明确的终点和标准化的围手术期管理,以潜在地阐明这两种手术之间的差异。应评估新策略以预防和治疗常见并发症,如胃排空延迟。